Your browser doesn't support javascript.
loading
Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience.
Chiron, Raphael; Hoefsloot, Wouter; Van Ingen, Jakko; Marchandin, Hélène; Kremer, Laurent; Morisse-Pradier, Hélène; Charriot, Jeremy; Mallet, Jean-Pierre; Herrmann, Jean-Louis; Caimmi, Davide; Moreau, Johan; Dumont, Yann; Godreuil, Sylvain; Bergeron, Anne; Drevait, Margot; Bouzat-Rossigneux, Elodie; Terrail, Nicolas; Andrejak, Claire; Veziris, Nicolas; Grenet, Dominique; Coudrat, Alexandre; Catherinot, Emilie.
Afiliação
  • Chiron R; HydroSciences Montpellier, Centre National de la Recherche pour la Santé (CNRS), Institut de Recherche pour le Développement (IRD), Université Montpellier, Montpellier, France.
  • Hoefsloot W; CF Center, University Hospital Centre Montpellier, Montpellier, France.
  • Van Ingen J; Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Marchandin H; Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Kremer L; HydroSciences Montpellier, Centre National de la Recherche pour la Santé (CNRS), Institut de Recherche pour le Développement (IRD), Université Montpellier, Montpellier, France.
  • Morisse-Pradier H; Service de Microbiologie et Hygiène Hospitalière, University Hospital Centre Nimes, Nimes, France.
  • Charriot J; Institut de Recherche en Infectiologie de Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique UMR 9004, Université Montpellier, Montpellier, France.
  • Mallet JP; Institut de Recherche en Infectiologie de Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM), Montpellier, France.
  • Herrmann JL; Quantif-LITIS Laboratory EA 4108, Rouen University, Rouen, France.
  • Caimmi D; Respiratory Diseases Department, University Hospital Centre Montpellier, Montpellier, France.
  • Moreau J; PhyMedExp, Institut National de la Santé et de la Recherche Médicale (INSERM) U1046, Université Montpellier, Montpellier, France.
  • Dumont Y; Respiratory Diseases Department, University Hospital Centre Montpellier, Montpellier, France.
  • Godreuil S; Université Paris-Saclay, Hopital Raymond Poincaré, GHU-AP-HP, Paris, France.
  • Bergeron A; Service de Microbiologie, Garches UVSQ, Institut National de la Santé et de la Recherche Médicale (INSERM), Montigny le Bretonneux, France.
  • Drevait M; CF Center, University Hospital Centre Montpellier, Montpellier, France.
  • Bouzat-Rossigneux E; PhyMedExp, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche pour la Santé (CNRS), Montpellier, France.
  • Terrail N; Paediatric and Respiratory Departments, University Hospital Centre Montpellier, CF Center, Montpellier, France.
  • Andrejak C; Laboratoire de bactériologie, University Hospital Centre Montpellier, MIVEGEC, IRD-CNRS-UM, Montpellier, France.
  • Veziris N; Laboratoire de bactériologie, University Hospital Centre Montpellier, MIVEGEC, IRD-CNRS-UM, Montpellier, France.
  • Grenet D; Service de Pneumologie, AP-HP, Hôpital Saint-Louis, Paris, France.
  • Coudrat A; Biostatistics and Clinical Epidemiology Research Team, Université Paris Diderot, Sorbonne Paris Cité, U1153 CRESS, Paris, France.
  • Catherinot E; CF Center, University Hospital Centre Montpellier, Montpellier, France.
Open Forum Infect Dis ; 9(10): ofac465, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36267258
ABSTRACT

Background:

Mycobacterium abscessus infections remain difficult to manage in both cystic fibrosis (CF) and non-CF patients and reported clinical outcomes are largely unsatisfactory. Clinical trial data are limited and no approved therapies are currently available for the management of M abscessus lung diseases. As an alternative, cohort studies may provide insightful information into the management of M abscessus pulmonary disease.

Methods:

Based on a retrospective observational cohort study, we investigated the safety and efficacy of amikacin liposome inhaled suspension (ALIS) as an adjunct to a standard antibiotic regimen for M abscessus lung infection in both CF and non-CF patients. We also assessed the association of patient drug compliance with culture conversion and clinical outcomes.

Results:

Twenty-six patients had long-term follow-up data available. Culture conversion was achieved in 54% (14/26) of the patients with no difference between CF and non-CF patients after an average treatment duration of 10 months. Patient treatment compliance was significantly better in the converter group compared to nonconverters with an odds ratio of 44.78 associated with good compared to poor patient compliance. Overall, 9 patients (35%) experienced an adverse event that led to treatment discontinuation.

Conclusions:

ALIS appears beneficial in both CF and non-CF populations with M abscessus lung disease.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França